OrbiMed

Verdiva Bio is a biopharmaceutical company specializing in the development of innovative therapies for patients with obesity and cardiometabolic disorders. The company focuses on creating more patient-friendly treatment options by targeting gut-brain biology, with a pipeline centered around multiple amylin molecules. This approach aims to enhance efficacy, improve tolerability, and facilitate healthier weight loss for individuals facing these health challenges.

Ottimo Pharma is a biopharmaceutical company dedicated to developing innovative cancer therapies for solid tumors. Its primary focus is Jankistomig, a bi-functional antibody that simultaneously targets two critical pathways in cancer growth: immune checkpoint inhibition and angiogenesis. By addressing these pathways concurrently, Ottimo Pharma aims to improve treatment outcomes and reduce the burden of cancer on patients and the healthcare system.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

Poxel is a biopharmaceutical company based in Lyon, France, focused on developing innovative drugs for metabolic diseases, with a primary emphasis on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009, Poxel's lead product is Imeglimin, an oral anti-diabetic candidate in Phase III clinical development that targets key organs affected by diabetes, such as the pancreas, liver, and muscles. The company is also advancing PXL770, an adenosine monophosphate-activated protein kinase enzyme in Phase IIa clinical trials for treating chronic metabolic diseases like NASH. Additionally, Poxel has licensing agreements for PXL007 (EYP001), an FXR agonist in Phase I study for hepatitis B and NASH, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I clinical trials for NASH.

Mirador Therapeutics specializes in developing precision medicine technologies to tackle immune-mediated inflammatory and fibrotic diseases. The company's core offering is a proprietary data analytics engine that integrates comprehensive patient molecular profiles, pinpoints novel therapeutic targets, and facilitates the creation of targeted diagnostics. This enables researchers and healthcare providers to tailor treatments to individual patients' genetics, potentially enhancing outcomes for those with chronic conditions.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

Adela is a company focused on developing innovative technologies for the early detection of cancer and other serious health conditions through routine blood testing. Utilizing a genome-wide methylome enrichment platform, Adela captures and analyzes information from the entire methylome, effectively identifying and targeting highly informative methylated regions of the genome for sequencing. This approach enables the detection of minimal residual disease and aids in tumor classification using plasma cell-free DNA methylomes. Adela's technology is designed to assist healthcare professionals in cancer detection, as well as in prenatal diagnostics, cardiology, and the monitoring of immune responses. Through its advancements, Adela aims to improve diagnostic accuracy and patient outcomes in the realm of high-morbidity and high-mortality conditions.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

LifeWell is a new entity formed through the merger of LifeCell’s diagnostics business and MFine.

MDClone Ltd. is a company that specializes in software development for analyzing medical records. Founded in 2016 and based in Beersheba, Israel, MDClone has created a platform that generates synthetic medical records for fictitious patients, thus mitigating the risk of disclosing actual patient data. This innovative platform, known as ADAMS, provides a self-service analytics environment that facilitates exploration and collaboration across the healthcare ecosystem. By enabling researchers and healthcare organizations to examine disease behaviors, treatment efficacy, and operational efficiencies, MDClone supports the advancement of medical research and improves patient outcomes while ensuring the protection of sensitive medical information. The company serves a diverse clientele that includes major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Nucleix Ltd. is a biotechnology company that specializes in the development, manufacture, and marketing of non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on detecting cancer through sensitive and specific tests that identify subtle changes in DNA methylation patterns. The company's flagship products include Bladder EpiCheck, a urine test designed for the monitoring of bladder cancer, and Lung EpiCheck, a blood test for the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix aims to enhance cancer monitoring and screening capabilities, ultimately improving treatment outcomes for patients. The company has established distribution partnerships in multiple countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.

Edge Medical Robotics, Inc. is a Shenzhen, China-based company that specializes in the design and development of advanced surgical equipment. Founded on May 4, 2017, the company is dedicated to researching and promoting cutting-edge smart technologies aimed at enhancing surgical safety and treatment efficacy. By focusing on the pursuit of excellence and refinement in its products, Edge Medical Robotics seeks to elevate health standards and improve overall social health outcomes.

Scout Bio, Inc. is a biotechnology company focused on advancing veterinary medicine through innovative therapies for chronic pet health conditions. Founded in 2016 and headquartered in Philadelphia, Pennsylvania, the company specializes in developing one-time treatments utilizing veterinary biotechnology and gene therapy. Scout Bio's offerings include therapies for conditions such as anemia associated with chronic kidney disease in cats, as well as a range of small molecular drugs, protein therapies, and gene therapies. Employing adeno-associated viral vector technology, Scout Bio aims to transform veterinary care by providing effective protein and monoclonal antibody therapeutics delivered through single intra-muscular injections, thereby enhancing the quality of life for pets and supporting veterinary professionals.

Humacyte, Inc. is a medical research and development company based in Morrisville, North Carolina, focusing on the creation and commercialization of human tissue-based products for regenerative medicine and vascular surgery. Established in 2004, the company specializes in developing acellular extracellular matrices derived from banked vascular smooth muscle cells, which are decellularized to prevent rejection. These engineered tissues are designed for use as vascular grafts, providing solutions for patients requiring vascular repair or replacement. Humacyte aims to deliver universally implantable bioengineered human tissues and organs, addressing various diseases, injuries, and chronic conditions while advancing the field of medicine.

Rimag is a prominent medical imaging service provider based in Shenzhen, China, founded in 2014. The company specializes in the operation of medical imaging centers and the development of relevant cloud technologies. Rimag offers a variety of imaging services, including MRI, CT, PET, X-ray, ultrasound, and mammography, catering to patients and healthcare consumers through its flagship imaging centers. In addition to its imaging services, Rimag is also involved in talent training, ensuring that the workforce is well-equipped to meet the demands of the healthcare industry. Through its comprehensive approach, Rimag aims to enhance the quality and accessibility of medical imaging services in China.

Adela is a company focused on developing innovative technologies for the early detection of cancer and other serious health conditions through routine blood testing. Utilizing a genome-wide methylome enrichment platform, Adela captures and analyzes information from the entire methylome, effectively identifying and targeting highly informative methylated regions of the genome for sequencing. This approach enables the detection of minimal residual disease and aids in tumor classification using plasma cell-free DNA methylomes. Adela's technology is designed to assist healthcare professionals in cancer detection, as well as in prenatal diagnostics, cardiology, and the monitoring of immune responses. Through its advancements, Adela aims to improve diagnostic accuracy and patient outcomes in the realm of high-morbidity and high-mortality conditions.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

EDDA Technology specializes in computer-assisted solutions for patient care management, particularly in the realm of imaging-guided cancer treatment. The company has developed the IQQA platform, which provides innovative imaging technologies that enhance workflow and patient care in surgical settings, including open, minimally invasive, and robotic surgeries. This platform supports a patient-specific and disease-targeted approach, facilitating a multidisciplinary strategy for cancer treatment. It encompasses the entire surgical process, offering features for pre-surgical planning and simulation, intra-operative guidance and monitoring, as well as post-operative follow-up evaluations and training. EDDA Technology's advancements aim to improve the efficiency and effectiveness of medical imaging and treatment protocols for healthcare professionals.

Nucleix Ltd. is a biotechnology company that specializes in the development, manufacture, and marketing of non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on detecting cancer through sensitive and specific tests that identify subtle changes in DNA methylation patterns. The company's flagship products include Bladder EpiCheck, a urine test designed for the monitoring of bladder cancer, and Lung EpiCheck, a blood test for the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix aims to enhance cancer monitoring and screening capabilities, ultimately improving treatment outcomes for patients. The company has established distribution partnerships in multiple countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.

Yisheng Biopharma Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and marketing of immuno-oncology products and vaccines. Founded in 2002 and headquartered in Beijing, the company operates in China, the United States, Cambodia, and Singapore. Yisheng Biopharma utilizes its novel PIKA immunomodulating technology to enhance immune responses against cancers and infectious diseases. Key products under development include YS-ON-001, an investigational therapy aimed at treating advanced solid tumors, as well as YS-HBV-001, a vaccine for hepatitis B, and a PIKA-based rabies vaccine designed for rapid protection against rabies infection. The company's innovative approach targets multiple immune pathways to improve treatment outcomes.

CoreMap, Inc. is a medical technology company based in Winooski, Vermont, focused on developing advanced diagnostic solutions for electrophysiologists treating atrial fibrillation. Incorporated in 2016, the company offers a micro-electrode solution that allows for sequential mapping of tissue properties, addressing significant challenges in the treatment of atrial fibrillation, such as poor spatial resolution and inadequate sample density. Additionally, CoreMap's ultra-high resolution electrodes provide detailed insights into cardiac activation, even during episodes of fibrillation. By enhancing the diagnostic capabilities of electrophysiologists, CoreMap aims to improve patient outcomes in the management of this complex condition.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, specializing in the discovery and development of antiviral drugs targeting respiratory syncytial virus (RSV). Founded in 2011, ReViral is focused on creating innovative first-in-class compounds, including a highly potent fusion inhibitor designed specifically for treating severe RSV infections, particularly in vulnerable populations such as neonates. By advancing these novel antiviral treatments, ReViral aims to address significant unmet medical needs and expand the antiviral market, ultimately improving patient outcomes for those affected by RSV.

MobileODT Ltd is a company specializing in the development of optical diagnostic devices and software services aimed at early cancer detection. Based in Tel Aviv, Israel, with an additional location in New York, MobileODT offers a range of products, including the FDA-cleared EVA COLPO, a portable and Internet-connected colposcope, and EVA SANE, a secure platform for managing patient information. The company's Enhanced Visual Assessment (EVA) System enhances the capabilities of healthcare providers, enabling them to conduct examinations comparable to those performed by expert practitioners. MobileODT's tools are utilized in various challenging environments and have been employed in over 40,000 procedures across 29 countries. The company's offerings also include applications for documenting cases of violence and abuse, as well as cloud-based solutions for managing patient data. With a growing presence in the United States, MobileODT is establishing itself as a leader in visual diagnostic technology, expanding into new markets and developing additional applications for diverse medical fields.

Perfuse Therapeutics is a biotechnology company dedicated to developing innovative therapies for eye diseases. The firm is focused on a novel mechanism aimed at improving retinal perfusion, which is crucial for addressing various retinal conditions. Initially targeting glaucoma, Perfuse Therapeutics aims to enhance blood flow to the retina, thereby enabling healthcare professionals to slow the progression of diseases such as non-proliferative diabetic retinopathy and retinal vein occlusion. Through its research and development efforts, the company seeks to offer effective treatment options that can significantly impact patient outcomes in the field of ophthalmology.

MDClone Ltd. is a company that specializes in software development for analyzing medical records. Founded in 2016 and based in Beersheba, Israel, MDClone has created a platform that generates synthetic medical records for fictitious patients, thus mitigating the risk of disclosing actual patient data. This innovative platform, known as ADAMS, provides a self-service analytics environment that facilitates exploration and collaboration across the healthcare ecosystem. By enabling researchers and healthcare organizations to examine disease behaviors, treatment efficacy, and operational efficiencies, MDClone supports the advancement of medical research and improves patient outcomes while ensuring the protection of sensitive medical information. The company serves a diverse clientele that includes major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Health Catalyst is a technology company that specializes in data and analytics solutions for healthcare organizations. The company offers a platform that organizes, normalizes, and links health-related data from various systems, making it accessible and searchable for all users, including those without technical expertise. Health Catalyst operates through two main segments: the Technology segment, which generates the majority of its revenue through cloud-based subscriptions, time-based licenses, and maintenance fees for its data platforms and analytics applications; and the Professional Services segment, which provides a range of services including analytics, implementation, strategic advisory, and outsourcing to help clients optimize their use of the technology. By integrating and analyzing healthcare data, Health Catalyst aims to enhance decision-making and improve outcomes in the healthcare sector.

Health Catalyst is a technology company that specializes in data and analytics solutions for healthcare organizations. The company offers a platform that organizes, normalizes, and links health-related data from various systems, making it accessible and searchable for all users, including those without technical expertise. Health Catalyst operates through two main segments: the Technology segment, which generates the majority of its revenue through cloud-based subscriptions, time-based licenses, and maintenance fees for its data platforms and analytics applications; and the Professional Services segment, which provides a range of services including analytics, implementation, strategic advisory, and outsourcing to help clients optimize their use of the technology. By integrating and analyzing healthcare data, Health Catalyst aims to enhance decision-making and improve outcomes in the healthcare sector.

Alphamab Oncology is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the research, development, manufacturing, and commercialization of innovative therapeutics for cancer treatment. The company utilizes proprietary platforms in bispecific antibodies and protein engineering to create a robust pipeline of oncology and immunology products. Key candidates in development include KN046, a bispecific monoclonal antibody immune checkpoint inhibitor targeting PD-L1 and CTLA-4, and KN026, an advanced anti-HER2 bispecific antibody. Additionally, KN019, an immunosuppressant fusion protein, and KN035, a PD-L1 inhibitor, are also progressing through clinical trials, addressing various solid tumors and autoimmune conditions. Founded in 2008, Alphamab Oncology is committed to developing next-generation therapies to meet global medical needs in oncology.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, specializing in the discovery and development of antiviral drugs targeting respiratory syncytial virus (RSV). Founded in 2011, ReViral is focused on creating innovative first-in-class compounds, including a highly potent fusion inhibitor designed specifically for treating severe RSV infections, particularly in vulnerable populations such as neonates. By advancing these novel antiviral treatments, ReViral aims to address significant unmet medical needs and expand the antiviral market, ultimately improving patient outcomes for those affected by RSV.

Asian Institute of Medical Sciences is a prominent super-specialty hospital located in Delhi NCR, India, with a capacity of 425 beds. The institute is committed to delivering accessible and affordable healthcare services and has received accreditation from both NABH and NABL. It offers a comprehensive range of medical services, including preventive, diagnostic, therapeutic, rehabilitative, and palliative care, all provided under one roof. The hospital is equipped with advanced facilities and aims to meet the healthcare and research needs of the modern era. It features 14 centers of excellence, including specialized departments for cancer treatment, bone marrow transplants, cardiac care, advanced surgery, neurology, urology, renal diseases, gastroenterology, and more, ensuring high-quality multi-specialty tertiary care for its patients.

MDClone Ltd. is a company that specializes in software development for analyzing medical records. Founded in 2016 and based in Beersheba, Israel, MDClone has created a platform that generates synthetic medical records for fictitious patients, thus mitigating the risk of disclosing actual patient data. This innovative platform, known as ADAMS, provides a self-service analytics environment that facilitates exploration and collaboration across the healthcare ecosystem. By enabling researchers and healthcare organizations to examine disease behaviors, treatment efficacy, and operational efficiencies, MDClone supports the advancement of medical research and improves patient outcomes while ensuring the protection of sensitive medical information. The company serves a diverse clientele that includes major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

MobileODT Ltd is a company specializing in the development of optical diagnostic devices and software services aimed at early cancer detection. Based in Tel Aviv, Israel, with an additional location in New York, MobileODT offers a range of products, including the FDA-cleared EVA COLPO, a portable and Internet-connected colposcope, and EVA SANE, a secure platform for managing patient information. The company's Enhanced Visual Assessment (EVA) System enhances the capabilities of healthcare providers, enabling them to conduct examinations comparable to those performed by expert practitioners. MobileODT's tools are utilized in various challenging environments and have been employed in over 40,000 procedures across 29 countries. The company's offerings also include applications for documenting cases of violence and abuse, as well as cloud-based solutions for managing patient data. With a growing presence in the United States, MobileODT is establishing itself as a leader in visual diagnostic technology, expanding into new markets and developing additional applications for diverse medical fields.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Guardant Health, Inc. is a precision oncology company headquartered in Redwood City, California, specializing in liquid biopsy tests for cancer diagnosis and treatment. The company provides a range of blood tests, including Guardant360, which measures various cancer-related genes for advanced stage cancer treatment selection, and GuardantOMNI, a broader gene panel that supports immuno-oncology research. Additionally, Guardant Health offers LUNAR-1 for detecting minimal residual disease and recurrence in cancer survivors, along with the development of LUNAR-2 for early cancer detection in high-risk individuals. The company also provides development services such as companion diagnostic development and clinical trial support to biopharmaceutical firms and medical institutions. Founded in 2011, Guardant Health is recognized for its innovative approach to addressing unmet needs in oncology through advanced technology and analytics.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Suraksha Diagnostics, established in 1992 in Kolkata, is a prominent provider of comprehensive pathology and radiology services. As one of the earliest diagnostic centers in the region, it has gained a reputation for accuracy and high-quality service. The company expanded rapidly, opening a second facility in Siliguri within three years, which has since become the largest diagnostic center in North Bengal, catering to patients from the surrounding areas and neighboring states. Suraksha Diagnostics continues to grow its footprint across Bengal, Bihar, and the Delhi NCR, offering specialized diagnostic tests in areas such as imaging, cardiology, neurology, and gastroenterology. The organization aims to enhance industry standards through a robust network of laboratory and imaging services, along with tailored offerings for its clientele.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

Ornim, Inc. is a biomedical technology company specializing in the development and distribution of non-invasive medical monitoring tools for measuring blood flow and oxygen saturation in patients. Founded in 2004 and based in Santa Clarita, California, with a research and development subsidiary in Israel, Ornim has created innovative products such as the CerOx and c-FLOW monitors. These devices utilize patented UTLight technology, which combines light and ultrasound to deliver real-time, continuous measurements of cerebral blood flow and oxygen saturation. The CerOx monitor is unique in the market for its ability to measure both parameters simultaneously, while the c-FLOW focuses solely on cerebral blood flow. Ornim's solutions are designed to enhance individualized patient care by providing critical insights into blood flow variations, thereby enabling informed clinical interventions. The company holds numerous patents, reflecting its commitment to overcoming the limitations of existing monitoring technologies, and aims to improve treatment outcomes and reduce healthcare costs through its innovative monitoring solutions.

MDClone Ltd. is a company that specializes in software development for analyzing medical records. Founded in 2016 and based in Beersheba, Israel, MDClone has created a platform that generates synthetic medical records for fictitious patients, thus mitigating the risk of disclosing actual patient data. This innovative platform, known as ADAMS, provides a self-service analytics environment that facilitates exploration and collaboration across the healthcare ecosystem. By enabling researchers and healthcare organizations to examine disease behaviors, treatment efficacy, and operational efficiencies, MDClone supports the advancement of medical research and improves patient outcomes while ensuring the protection of sensitive medical information. The company serves a diverse clientele that includes major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Response Biomedical Corp. is a Vancouver-based company that specializes in the research, development, commercialization, and distribution of diagnostic technologies. The company focuses on rapid on-site diagnostic tests for medical central-lab testing, point of care (POC) testing, and environmental testing markets. Its primary product is the RAMP system, a portable fluorescence immunoassay-based diagnostic platform that delivers laboratory-quality results quickly and conveniently through various formats, including hand-held devices and single-use test cartridges. Response Biomedical's tests are designed for early detection of conditions such as heart attacks, congestive heart failure, and influenza, as well as environmental threats like the West Nile Virus and biodefense applications for detecting agents such as anthrax and ricin. The company distributes its products globally, targeting markets in the United States, Asia, Latin and South America, Europe, the Middle East, and Canada. Founded in 1980, Response Biomedical is committed to improving patient management in acute care settings through efficient and rapid diagnostic solutions.

Nucleix Ltd. is a biotechnology company that specializes in the development, manufacture, and marketing of non-invasive molecular cancer diagnostic tests. Founded in 2008 and headquartered in Rehovot, Israel, with an additional office in San Diego, California, Nucleix focuses on detecting cancer through sensitive and specific tests that identify subtle changes in DNA methylation patterns. The company's flagship products include Bladder EpiCheck, a urine test designed for the monitoring of bladder cancer, and Lung EpiCheck, a blood test for the early detection of lung cancer. By leveraging proprietary biomarker assays, Nucleix aims to enhance cancer monitoring and screening capabilities, ultimately improving treatment outcomes for patients. The company has established distribution partnerships in multiple countries, including Israel, the Netherlands, Turkey, Russia, Italy, and Denmark.

Guardant Health, Inc. is a precision oncology company headquartered in Redwood City, California, specializing in liquid biopsy tests for cancer diagnosis and treatment. The company provides a range of blood tests, including Guardant360, which measures various cancer-related genes for advanced stage cancer treatment selection, and GuardantOMNI, a broader gene panel that supports immuno-oncology research. Additionally, Guardant Health offers LUNAR-1 for detecting minimal residual disease and recurrence in cancer survivors, along with the development of LUNAR-2 for early cancer detection in high-risk individuals. The company also provides development services such as companion diagnostic development and clinical trial support to biopharmaceutical firms and medical institutions. Founded in 2011, Guardant Health is recognized for its innovative approach to addressing unmet needs in oncology through advanced technology and analytics.

Eurolife Healthcare is a manufacturer and distributor of a diverse array of healthcare formulations tailored for various medical applications. The company specializes in producing generic pharmaceutical products, including intravenous infusions, ophthalmic solutions, sterilized water for injections, tablets, capsules, ointments, creams, and other formulations. Eurolife Healthcare emphasizes high-quality and sterile packaging to ensure that healthcare providers can effectively meet medical supply demands. Its product offerings extend to systems such as the eurohead infusion system, classic infusion therapy, and specialized solutions like Lifeflow and Germkill, designed to address specific therapeutic needs in the healthcare sector.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, specializing in the discovery and development of antiviral drugs targeting respiratory syncytial virus (RSV). Founded in 2011, ReViral is focused on creating innovative first-in-class compounds, including a highly potent fusion inhibitor designed specifically for treating severe RSV infections, particularly in vulnerable populations such as neonates. By advancing these novel antiviral treatments, ReViral aims to address significant unmet medical needs and expand the antiviral market, ultimately improving patient outcomes for those affected by RSV.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Sikka Software is a pioneering company in the retail healthcare market, offering a cloud-based business intelligence platform that leverages artificial intelligence and predictive analytics. Its award-winning single API platform is designed to support non-physician practices, including dentistry, veterinary care, optometry, chiropractic, orthodontic, and oral surgery. With 35,000 practice installations and connectivity to 96% of the retail healthcare market, Sikka Software enables healthcare providers to optimize their operations through a suite of applications that integrate various practice management and financial systems. The platform hosts 50 applications developed by numerous suppliers, including Fortune 500 companies, alongside four proprietary applications from Sikka. With a vision to create a real-time global platform that connects patients, providers, and suppliers, Sikka addresses a services market exceeding $260 billion annually. The Sikka ONE API was recognized with the Best Health API Award in 2019, highlighting its innovation and impact in the industry.

Wuhan Eyegood Ophthalmic Hospital is a specialized medical facility that provides comprehensive ophthalmology services. Established in 2003 and located in Wuhan, China, the hospital focuses on the diagnosis and treatment of various eye conditions. With a commitment to delivering high-quality eye care, Eyegood Ophthalmic Hospital utilizes advanced medical technologies and techniques to ensure optimal patient outcomes. The hospital serves a diverse patient population, addressing a wide range of ophthalmic needs.

Dimension Therapeutics, Inc. is a gene therapy company based in Cambridge, Massachusetts, specializing in the development of innovative treatments for rare and metabolic diseases associated with the liver. Founded in 2013, the company has a robust pipeline of gene therapy programs, including DTX101 and DTX201 for hemophilia B and A, respectively. Additionally, its portfolio encompasses DTX301 for ornithine transcarbamylase deficiency, DTX401 for glycogen storage disease type Ia, DTX501 for phenylketonuria, DTX701 for Wilson disease, and DTX601 for citrullinemia type I. Dimension Therapeutics collaborates with REGENX Biosciences, gaining access to a significant portfolio of patents related to adeno-associated virus (AAV) therapeutics. This collaboration supports the company's aim to advance its gene therapy platform and enhance its product development capabilities in the treatment of rare diseases. Dimension Therapeutics operates as a subsidiary of Ultragenyx Pharmaceutical Inc. since November 2017.

Rapid Pathogen Screening, Inc., established in 2004 and headquartered in Sarasota, Florida, is a biotechnology company specializing in the development, manufacture, and marketing of point-of-care diagnostic tests. The company's innovative technology platform enables the creation of cost-effective tests for rapid identification of infectious diseases and inflammatory conditions. Notable products include AdenoPlus, a test for adenoviral conjunctivitis, and InflammaDry, a dry eye test. These tests are designed to be easily administered by clinicians with minimal training and equipment. Additionally, through U.S. government contracts, the company is developing tests for bio-terrorism agents and chemical nerve agent blood toxins. Rapid Pathogen Screening's products are distributed globally through various healthcare providers and distributors.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

Unilife is a U.S.-based medical device and technology company specializing in the design, development, manufacturing, and supply of innovative delivery systems for injectable drugs and vaccines. The company has created a drug delivery platform that offers smart, reusable auto injectors, allowing patients to control the speed of injection. This technology enhances the delivery of therapies that come in standard prefilled barrels, thereby supporting pharmaceutical and biotechnology companies in providing injectable biologics, drugs, and vaccine products. Through its focus on differentiated delivery systems, Unilife aims to improve patient experiences and outcomes in drug administration.

Dimension Therapeutics, Inc. is a gene therapy company based in Cambridge, Massachusetts, specializing in the development of innovative treatments for rare and metabolic diseases associated with the liver. Founded in 2013, the company has a robust pipeline of gene therapy programs, including DTX101 and DTX201 for hemophilia B and A, respectively. Additionally, its portfolio encompasses DTX301 for ornithine transcarbamylase deficiency, DTX401 for glycogen storage disease type Ia, DTX501 for phenylketonuria, DTX701 for Wilson disease, and DTX601 for citrullinemia type I. Dimension Therapeutics collaborates with REGENX Biosciences, gaining access to a significant portfolio of patents related to adeno-associated virus (AAV) therapeutics. This collaboration supports the company's aim to advance its gene therapy platform and enhance its product development capabilities in the treatment of rare diseases. Dimension Therapeutics operates as a subsidiary of Ultragenyx Pharmaceutical Inc. since November 2017.

Unilife is a U.S.-based medical device and technology company specializing in the design, development, manufacturing, and supply of innovative delivery systems for injectable drugs and vaccines. The company has created a drug delivery platform that offers smart, reusable auto injectors, allowing patients to control the speed of injection. This technology enhances the delivery of therapies that come in standard prefilled barrels, thereby supporting pharmaceutical and biotechnology companies in providing injectable biologics, drugs, and vaccine products. Through its focus on differentiated delivery systems, Unilife aims to improve patient experiences and outcomes in drug administration.

Ornim, Inc. is a biomedical technology company specializing in the development and distribution of non-invasive medical monitoring tools for measuring blood flow and oxygen saturation in patients. Founded in 2004 and based in Santa Clarita, California, with a research and development subsidiary in Israel, Ornim has created innovative products such as the CerOx and c-FLOW monitors. These devices utilize patented UTLight technology, which combines light and ultrasound to deliver real-time, continuous measurements of cerebral blood flow and oxygen saturation. The CerOx monitor is unique in the market for its ability to measure both parameters simultaneously, while the c-FLOW focuses solely on cerebral blood flow. Ornim's solutions are designed to enhance individualized patient care by providing critical insights into blood flow variations, thereby enabling informed clinical interventions. The company holds numerous patents, reflecting its commitment to overcoming the limitations of existing monitoring technologies, and aims to improve treatment outcomes and reduce healthcare costs through its innovative monitoring solutions.

RedHill Biopharma Ltd. is a specialty biopharmaceutical company headquartered in Tel Aviv, Israel, with a primary focus on gastrointestinal and infectious diseases. The company develops and promotes several gastrointestinal drugs, including Movantik for opioid-induced constipation, Talicia for treating Helicobacter pylori infection, and Aemcolo for travelers' diarrhea. RedHill's late-stage clinical development programs include RHB-204, aimed at treating pulmonary nontuberculous mycobacteria infections; RHB-104 for Crohn's disease; and RHB-102 (Bekinda), which has shown promise in Phase 3 studies for acute gastroenteritis and gastritis. Additionally, the company is advancing RHB-107, a serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and opaganib, which is being investigated for various conditions, including COVID-19. Founded in 2009, RedHill Biopharma is committed to innovation in the management of gastrointestinal and infectious diseases.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Amoy Diagnostics is a research and development based diagnostic company focusing on molecular diagnostics for oncology precision medicine. AmoyDx has a portfolio of molecular diagnostic assays. Based on multiple technology platforms including PCR, NGS, FISH and IHC, AmoyDx's core product categories include single gene testing kits, multi-gene testing panels, NGS panels, and NGS analytical systems.

Singulex, Inc. is an immunodiagnostics company specializing in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company develops the Sgx Clarity System, an advanced in vitro diagnostics platform that detects low abundance biomarkers with high sensitivity, down to femtograms per milliliter. This system supports cardiovascular health management through services aimed at clinicians and personalized wellness programs for patients. Singulex offers ultra-sensitive immunoassay solutions and laboratory testing services that enhance patient care by facilitating proactive health management and aiding in the discovery of new therapeutics. The company serves a diverse clientele including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Singulex, originally established as BioProfile Corporation in 1997, rebranded in 2003 and is headquartered in Alameda, California, with an additional office in Basel, Switzerland.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Treato Ltd. operates a health information platform that aggregates and analyzes patient experiences sourced from the internet, particularly from social media, blogs, and forums. Founded in 2008 and based in Yehud, Israel, Treato provides valuable insights for patients, healthcare professionals, pharmaceutical companies, and other healthcare organizations. The platform utilizes advanced Natural Language Processing to extract relevant information from a vast amount of patient-written content, allowing a comprehensive understanding of patients’ thoughts and attitudes toward medications and health conditions. Additionally, Treato Pharma offers a specialized brand intelligence service that equips pharmaceutical marketers with real-time analytics, helping them understand patient opinions and competitive dynamics. This dual approach not only supports informed healthcare decisions for patients and caregivers but also enhances strategic marketing efforts within the pharmaceutical industry.

BioLineRx Ltd. is a clinical-stage biopharmaceutical development company based in Modi’in, Israel, specializing in oncology. The company's development pipeline includes several therapeutic candidates, such as BL-8040, a peptide designed for treating solid tumors, hematological malignancies, and facilitating stem cell mobilization. Another key candidate is AGI-134, an immuno-oncology agent aimed at solid tumors. Additionally, BioLineRx has developed BL-5010, a proprietary pen-like applicator intended for the non-surgical removal of skin lesions. The company has established collaborations with prominent organizations, including MSD for cancer immunotherapy, MD Anderson Cancer Center to explore the combination of BL-8040 with KEYTRUDA in pancreatic cancer, and Genentech Inc. for studies involving BL-8040 and TECENTRIQ in solid tumors. Founded in 2003, BioLineRx is focused on addressing unmet medical needs and improving existing therapies in the pharmaceutical market.

CardiAQ Valve Technologies is a privately held company dedicated to advancing heart valve replacement procedures. Its primary focus is on developing innovative techniques for transcatheter mitral valve implantation (TMVI), aiming to enable physicians to implant mitral valves within a beating heart without the need for open-heart surgery.

Ornim, Inc. is a biomedical technology company specializing in the development and distribution of non-invasive medical monitoring tools for measuring blood flow and oxygen saturation in patients. Founded in 2004 and based in Santa Clarita, California, with a research and development subsidiary in Israel, Ornim has created innovative products such as the CerOx and c-FLOW monitors. These devices utilize patented UTLight technology, which combines light and ultrasound to deliver real-time, continuous measurements of cerebral blood flow and oxygen saturation. The CerOx monitor is unique in the market for its ability to measure both parameters simultaneously, while the c-FLOW focuses solely on cerebral blood flow. Ornim's solutions are designed to enhance individualized patient care by providing critical insights into blood flow variations, thereby enabling informed clinical interventions. The company holds numerous patents, reflecting its commitment to overcoming the limitations of existing monitoring technologies, and aims to improve treatment outcomes and reduce healthcare costs through its innovative monitoring solutions.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, founded in 2007. It specializes in genetic screening for inherited diseases, aiming to transform reproductive medicine by providing actionable information to physicians and patients. The company offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. Additionally, Good Start Genetics provides a comprehensive array of genetic carrier screening tests through its GoodStart Select program, utilizing advanced next-generation DNA sequencing technology along with other established genetic screening methods. This focus on high carrier detection rates and commitment to customer care and genetic counseling positions the company as a leader in the field of pre-pregnancy genetic testing and diagnostics. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

Singulex, Inc. is an immunodiagnostics company specializing in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company develops the Sgx Clarity System, an advanced in vitro diagnostics platform that detects low abundance biomarkers with high sensitivity, down to femtograms per milliliter. This system supports cardiovascular health management through services aimed at clinicians and personalized wellness programs for patients. Singulex offers ultra-sensitive immunoassay solutions and laboratory testing services that enhance patient care by facilitating proactive health management and aiding in the discovery of new therapeutics. The company serves a diverse clientele including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Singulex, originally established as BioProfile Corporation in 1997, rebranded in 2003 and is headquartered in Alameda, California, with an additional office in Basel, Switzerland.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Kerala Institute of Medical Sciences is a multi-specialty tertiary care hospital located in Thiruvananthapuram, India, founded in 2002. It is dedicated to providing high-quality medical care through a team of specialists and advanced technology, ensuring that healthcare is both affordable and accessible to the community. The institution encompasses a range of services, from primary to quaternary care, including health check programs, emergency services, and specialized clinics. Additionally, it emphasizes education and research, offering 20 DNB programmes, fellowships, and international courses across various specialties. The Kerala Institute of Medical Sciences also includes a College of Nursing, an Institute of Skill Development, and a Paramedical Institute, thereby contributing to the training of healthcare professionals and enhancing the standard of patient care.

Roka Bioscience specializes in the development of rapid and accurate molecular assays and instrument systems aimed at the food safety industry. The company's latest innovation, the Atlas System, introduces advanced molecular rapid pathogen testing, which enhances laboratory efficiency through automation and user-friendly design. By focusing on innovative testing solutions, Roka Bioscience aims to assist food manufacturers in minimizing risks, safeguarding their brands, and addressing the growing demands for testing in the sector.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Roka Bioscience specializes in the development of rapid and accurate molecular assays and instrument systems aimed at the food safety industry. The company's latest innovation, the Atlas System, introduces advanced molecular rapid pathogen testing, which enhances laboratory efficiency through automation and user-friendly design. By focusing on innovative testing solutions, Roka Bioscience aims to assist food manufacturers in minimizing risks, safeguarding their brands, and addressing the growing demands for testing in the sector.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, founded in 2007. It specializes in genetic screening for inherited diseases, aiming to transform reproductive medicine by providing actionable information to physicians and patients. The company offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. Additionally, Good Start Genetics provides a comprehensive array of genetic carrier screening tests through its GoodStart Select program, utilizing advanced next-generation DNA sequencing technology along with other established genetic screening methods. This focus on high carrier detection rates and commitment to customer care and genetic counseling positions the company as a leader in the field of pre-pregnancy genetic testing and diagnostics. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Singulex, Inc. is an immunodiagnostics company specializing in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company develops the Sgx Clarity System, an advanced in vitro diagnostics platform that detects low abundance biomarkers with high sensitivity, down to femtograms per milliliter. This system supports cardiovascular health management through services aimed at clinicians and personalized wellness programs for patients. Singulex offers ultra-sensitive immunoassay solutions and laboratory testing services that enhance patient care by facilitating proactive health management and aiding in the discovery of new therapeutics. The company serves a diverse clientele including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Singulex, originally established as BioProfile Corporation in 1997, rebranded in 2003 and is headquartered in Alameda, California, with an additional office in Basel, Switzerland.

ForteBio is a life science company that specializes in developing analytical systems for the rapid and real-time quantification and characterization of proteins and their interactions. The company offers a range of instruments known as the Octet family, designed to provide scientists with detailed information about biomolecular interactions in micro-volume sample sizes. These systems facilitate the analysis of proteins, peptides, DNA, RNA, and small molecules in a microplate format. Among its key products are the Octet RED, which enables quantitation and kinetic analysis while supporting small molecule screening, as well as the Octet Q and QK models, which also focus on quantitation and kinetics. Through these advanced tools, ForteBio aims to enhance research capabilities in the field of biomolecular interactions.

Innovative Spinal Technologies is a spine technology company based in Mansfield, Massachusetts, established in 2002. The company specializes in the development of motion preservation and minimally invasive treatments for spinal disorders. Its product portfolio includes the AXIENT Dynamic Fixation system, a pedicle screw-based motion system, and the PARAMOUNT Lumbar Fusion System, designed for lumbar fusion procedures in various surgical approaches, including minimally invasive and open techniques. Additionally, the PARAMOUNT MIS Pedicle Screw System caters to both single and multi-level procedures, while the PARAMOUNT Open Pedicle Screw System is tailored for minimally invasive lumbar fusion. The PARAMOUNT VBR is specifically engineered for a minimally invasive transforaminal approach, reflecting the company’s commitment to advancing spinal care through innovative technologies.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Gelesis, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for gastrointestinal-related chronic diseases, particularly obesity and its associated conditions. Founded in 2006, Gelesis utilizes a mechanobiology technology platform to create first-in-class therapeutics. Its flagship product, PLENITY, is an FDA-cleared, orally administered aid for weight management, comprised of hydrogel particles that expand in the stomach to promote a feeling of fullness and help reduce caloric intake. The company's pipeline also includes potential treatments for non-alcoholic fatty liver disease, type 2 diabetes, and chronic idiopathic constipation, addressing a range of metabolic and digestive health issues.

Singulex, Inc. is an immunodiagnostics company specializing in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company develops the Sgx Clarity System, an advanced in vitro diagnostics platform that detects low abundance biomarkers with high sensitivity, down to femtograms per milliliter. This system supports cardiovascular health management through services aimed at clinicians and personalized wellness programs for patients. Singulex offers ultra-sensitive immunoassay solutions and laboratory testing services that enhance patient care by facilitating proactive health management and aiding in the discovery of new therapeutics. The company serves a diverse clientele including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Singulex, originally established as BioProfile Corporation in 1997, rebranded in 2003 and is headquartered in Alameda, California, with an additional office in Basel, Switzerland.

Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.

Innovative Spinal Technologies is a spine technology company based in Mansfield, Massachusetts, established in 2002. The company specializes in the development of motion preservation and minimally invasive treatments for spinal disorders. Its product portfolio includes the AXIENT Dynamic Fixation system, a pedicle screw-based motion system, and the PARAMOUNT Lumbar Fusion System, designed for lumbar fusion procedures in various surgical approaches, including minimally invasive and open techniques. Additionally, the PARAMOUNT MIS Pedicle Screw System caters to both single and multi-level procedures, while the PARAMOUNT Open Pedicle Screw System is tailored for minimally invasive lumbar fusion. The PARAMOUNT VBR is specifically engineered for a minimally invasive transforaminal approach, reflecting the company’s commitment to advancing spinal care through innovative technologies.

Amnis manufactures and supplies flow cytometry products and services. Their technology is used in research and clinical studies with biomedical and therapeutic applications, including investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients.